140 results
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
25 Mar 24
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
4:05pm
include statements about our business strategy, timeline and other goals, plans and prospects, including our commercialization plans respecting PEDMARK
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeline
8-K
EX-10.1
e1ydfv6s8en
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
8-K/A
EX-99.1
3b3ui1qwlji yw
6 Mar 24
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
4:07pm
8-K
EX-99.1
5js54pne4uf43581vt
29 Feb 24
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
4:04pm
8-K
EX-99.1
pcyp8 49ch
5 Dec 23
Fennec Announces Incremental $5 Million Investment from Petrichor
8:51pm
8-K
EX-99.1
jbcqe m83tnnghqkn
6 Nov 23
Fennec Pharmaceuticals Announces Third Quarter 2023
7:38pm
8-K/A
EX-99.1
4teasazc1m1 or3
7 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:51am
8-K
EX-99.1
0hj4 q0t9cllu2vgye
4 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:58am
8-K
EX-99.1
kfexc y06zpco
4 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:57am
8-K
EX-99.1
5u3z26
6 Jun 23
Other Events
5:39pm